<DOC>
	<DOCNO>NCT01301157</DOCNO>
	<brief_summary>This study evaluate efficacy safety M518101 dose relationship among two dos M518101 placebo male female plaque psoriasis patient .</brief_summary>
	<brief_title>Study Investigate Efficacy Safety M518101 Plaque Psoriasis Patients</brief_title>
	<detailed_description>This study evaluate efficacy safety M518101 dose response relationship among two dos M518101 placebo male female plaque psoriasis patient confirm persistence effect M518101 .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<criteria>1. Who able willing give sign informed consent 2. Who male female age 18 year old plaque psoriasis confirm Investigator . 3. Who less 20 % body surface area ( BSA ) afflict plaque 4. Who neither pregnant breastfeeding , plan become pregnant study . 1. Who history allergy vitamin D3 derivative preparation . 2. Who history relevant drug hypersensitivity . 3. Who history contact dermatitis induce topical medicine . 4. Who pregnant lactate . 5. Who renal hepatic insufficiency , clinically significant cardiac , renal hepatic disease . 6. Who deem eligible determined medical history , physical examination clinical laboratory safety test . 7. Who clinically relevant history presence disease surgical history psoriasis likely affect conduct study . 8 . Whose serum calcium level exceed upper limit reference range 9. Who use investigational medicinal product and/or participate clinical study within 60 day day sign ICF . 10. Who treat systemic therapy within 2 week day sign ICF washout period . 11. Who treat biologics within 5 halflives biologics day randomization . 12. Who treat topical therapy washout period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>